Multiple Myeloma

Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

Dr Krina Patel presents the case of a relatively young patient with relapsed multiple myeloma, and Dr Caitlin Costello shares her approaches to treating relapsed/refractory multiple myeloma in her clinical practice.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Assessing Response and Duration of Treatment in Transplant-Eligible NDMM

Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Shambavi Richard, MD;Joshua Richter, MD

Recap: A Review of Selinexor Combination Therapies in Relapsed/Refractory Multiple Myeloma

A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.

$Recap: A Review of Selinexor Combination Therapies in Relapsed/Refractory Multiple Myeloma$

ONCOLOGY Staff

November 15th 2022

In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.

Data from a study indicated that durable minimal residual disease negativity was associated with stool butyrate production in patients with multiple myeloma who had plant-based diets undergoing treatment with lenalidomide maintenance.

Plant-Based Diet, Stool Butyrate Associated with Long-Lasting MRD Negativity in Multiple Myeloma

Ariana Pelosci

November 14th 2022

Data from a study indicated that durable minimal residual disease negativity was associated with stool butyrate production in patients with multiple myeloma who had plant-based diets undergoing treatment with lenalidomide maintenance.

Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM

Alfred Garfall, MD;Edward A. Stadtmauer, MD;Dan Vogl, MD;Sandara Susanibar-Adaniya, MD

November 11th 2022

Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.

Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma

Alfred Garfall, MD;Edward A. Stadtmauer, MD;Dan Vogl, MD;Sandara Susanibar-Adaniya, MD

November 11th 2022

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.

Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina K. Patel, MD

Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM

The panel explains their goals of treatment for older patients with transplant-ineligible multiple myeloma, and how they determine treatment duration.

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina K. Patel, MD

Evaluating MRD-Guided Therapy in Patients with NDMM

Rafael Fonseca, MD, and Krina Patel, MD, discuss the standard treatment approaches for frail or elderly patients with transplant-ineligible multiple myeloma.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Induction Regimens in Transplant-Eligible NDMM: Clinical Trial Data

Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Shambavi Richard, MD;Joshua Richter, MD

Patient Case 1: A 54-Year-Old Woman With Transplant-Eligible NDMM

Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Joshua Richter, MD;Shambavi Richard, MD

Phase 3 DREAMM-3 Trial Misses PFS End Point for Belantamab Mafodotin in R/R Multiple Myeloma

Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.

Ariana Pelosci

November 8th 2022

The primary end point of progression-free survival was not met in the phase 3 DREAMM-3 trial which investigated belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Race/Ethnicity and Socioeconomic Status Appear to Affect Survival Outcomes in Multiple Myeloma

Nicholas Wrigley

November 7th 2022

Higher neighborhood socioeconomic status improves long-term survival in patients with multiple myeloma regardless of overlapping disparities between racial and ethnic groups.

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff

November 5th 2022

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.

First-Line Treatment Options in Transplant-Ineligible NDMM

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina K. Patel, MD

Measuring Treatment Response in Transplant-Eligible NDMM

Dr Caitlin Costello presents the case of a patient with transplant-ineligible multiple myeloma and sparks a conversation on the available treatment regimens.

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina K. Patel, MD

Consolidation and Maintenance Therapy in Transplant-Eligible NDMM

A look at how to measure an adequate treatment response in patients with transplant-ineligible newly-diagnosed multiple myeloma, and treatment regimens for high-risk patients.

Alfred Garfall, MD;Edward A. Stadtmauer, MD;Dan Vogl, MD;Sandara Susanibar-Adaniya, MD

Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma

A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.

Alfred Garfall, MD;Edward A. Stadtmauer, MD;Dan Vogl, MD;Sandara Susanibar-Adaniya, MD

Elranatamab Granted Breakthrough Therapy Designation by FDA for Relapsed/Refractory Myeloma

Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.

$Patients with relapsed/refractory multiple myeloma may benefit from treatment with elranatamab, which was granted breakthrough therapy designation by the FDA.$

Hayley Virgil

Recap: Recent Research in Multiple Myeloma

Patients with relapsed/refractory multiple myeloma may benefit from treatment with elranatamab, which was granted breakthrough therapy designation by the FDA.

ONCOLOGY Staff

Cross Q&A: Belantamab for Multiple Myeloma Treatment

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.

Data on Real-World Use of Belantamab Mafodotin in R/R MM

Malin Hultcrantz, MD, PhD, questions Shonali Midha, MD, about the data she presented on belantamab mafodotin in patients with relapsed/refractory multiple myeloma.